Clinical Trial

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies. The names of the drugs involved in this study are: * Venetoclax * Decitabine * Navitoclax
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2022-07-07; most recent amendment 2026-01-26.
Status change: Recruiting → Active, Not Recruiting 2024-07-21
Status change: Not Yet Recruiting → Recruiting 2022-07-20
Trial Details
NCT Number NCT05455294
Lead Sponsor Jacqueline Garcia, MD
Collaborators: AbbVie
Conditions Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia, Myeloproliferative Neoplasm
Enrollment 16 participants
Start Date 2022-07-18
Primary Completion 2024-04-17 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-28